Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Cencora, one of the world's largest pharmaceutical companies, has announced the acquisition of Retina Consultants of America for $4.6 billion. This deal significantly enhances Cencora's specialty business, expanding its reach into the ophthalmology sector with a practice that includes 300 retina specialists. The acquisition is seen as a strategic move to bolster vertical integration in the healthcare market, particularly in light of upcoming biosimilar launches. Additionally, Laser Photonics has completed its acquisition of Control Micro Systems, marking its entry into the pharmaceutical laser equipment market.
Vertical integration FTW: @CencoraGlobal $COR announces acquisition of Retina Consultants of America (#physician practice MSO). Again, private equity facilitates #wholesaler ownership in downstream customers. Smart given upcoming #biosimilar launches. https://t.co/essFv7oa8M
‼️‼️‼️ WOW!!! Perhaps wishing that the news would get buried in the post-election noise, today Cencora (one of world’s largest PHARMA companies) spend $4.6 BILLION buying a massive practice of 300 retina specialists. Why is this bad? Doctors’ bosses will want them to prescribe… https://t.co/w22vZrQaGX
Cencora bolsters specialty business with $4.6 bln deal for Retina Consultants of America https://t.co/lnMUokcOK0 https://t.co/y117JMzH60
